ArticleNature communications2026
Intracellular artificial DNA receptor-loaded gelated cells for aflatoxin theranostics.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Aflatoxin B1 (AFB1) is one of the most common mycotoxins, which causes severe hepatic damage and even liver cancer. However, the development of specific tools for AFB1 diagnosis and detoxification remains elusive. Herein, we develop a DNA receptor-loaded gelated cell (DR-GC)-based adsorbent for specifically capturing and detecting AFB1, both in vitro and in vivo. In this system, fragile living cells are transformed into robust GCs using an intracellular hydrogel technique, and then loaded with aptamer-based artificial DNA receptors inside cells via a polymer-assisted strategy. These intracellular DNA receptors are excluded from a hostile environment, which exhibits high stability and retains their functionality even in complex biological media. Consequently, DR-GCs can be used to sensitively detect AFB1 and efficiently eliminate AFB1, both in vitro and in vivo. We also demonstrate the excellent therapeutic efficacy of DR-GCs using AFB1-treated male mouse models. Overall, this study is anticipated to offer useful solutions to the development of safe and effective tools for the diagnosis, elimination and treatment of mycotoxins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.